Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072124 · ClinicalTrials.gov registry record · Phase 3
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00072124: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00072124 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072124, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Complete metastasectomy may be an effective treatment for metastatic melanoma and may improve quality of life and help patients live longer and more comfortably. It is not yet known whether complete metastasectomy is more effective than chemotherapy in treating stage IV melanoma. PURPOSE: This randomized phase III trial is studying dacarbazine and/or cisplatin to see how well they work compared to complete metastasectomy in treating patients with stage IV melanoma.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- DRUG dacarbazine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072124
The ClinicalTrials.gov registry entry for NCT00072124 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00072124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072124 about?
NCT00072124 is a clinical study titled "Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Complete metastasectomy may be an effective treatment for metastatic melanoma and may improve quality of life and help patients live longer ...
What is the current status of trial NCT00072124?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00072124?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00072124?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.